FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1588931589> ?p ?o ?g. }

• W1588931589 endingPage "642" @default.
• W1588931589 startingPage "636" @default.
• W1588931589 abstract "To compare the overall survival (OS) of patients with advanced lung adenocarcinoma in China before and after the approved use of gefitinib, and analyze clinical factors that may affect OS.Clinical data of 558 patients with advanced lung adenocarcinoma who received chemotherapy from January 2002 to December 2010 were retrospectively analyzed. According to the matched-pair case-control study design, 255 patients who only received chemotherapy and 255 patients who received gefitinib treatment after its approval were stringently matched by age, gender, and smoking history and enrolled in the study. Clinical factors including age, gender, smoking history, Eastern Cooperative Oncology Group (ECOG) performance status (PS), tumor stage, organ metastasis, and the number of prior chemotherapies were analyzed to determine their correlations with OS.The median survival time (MST) of the 510 enrolled patients with advanced lung adenocarcinoma was 22.8 months. The MST of the patients who received gefitinib treatment was significantly longer than that of patients who did not receive gefitinib treatment (33.5 vs. 14.1 months, P < 0.001). The OS in patients who received gefitinib treatment was significantly longer than in patients who did not receive gefitinib treatment in almost all clinical factor-based subgroups, including age, gender, smoking history, ECOG PS 0-1, tumor stage, the presence or absence of lung, pleural, bone, brain, adrenal gland and liver metastasis, and the number of prior chemotherapies (all P < 0.001), except in the ECOG PS ≥2 subgroup.Gefitinib treatment significantly improved the survival of patients with advanced lung adenocarcinoma in China." @default.
• W1588931589 created "2016-06-24" @default.
• W1588931589 creator A5003642180 @default.
• W1588931589 creator A5008382997 @default.
• W1588931589 creator A5027834918 @default.
• W1588931589 creator A5045176687 @default.
• W1588931589 creator A5048001385 @default.
• W1588931589 creator A5053708169 @default.
• W1588931589 creator A5055470683 @default.
• W1588931589 creator A5065208984 @default.
• W1588931589 creator A5065246588 @default.
• W1588931589 creator A5068920157 @default.
• W1588931589 creator A5078718147 @default.
• W1588931589 date "2015-05-21" @default.
• W1588931589 modified "2023-10-17" @default.
• W1588931589 title "Survival of patients with advanced lung adenocarcinoma before and after approved use of gefitinib in C hina" @default.
• W1588931589 cites W1523413020 @default.
• W1588931589 cites W1839238860 @default.
• W1588931589 cites W1978726963 @default.
• W1588931589 cites W2049938167 @default.
• W1588931589 cites W2067790939 @default.
• W1588931589 cites W2068245411 @default.
• W1588931589 cites W2083336755 @default.
• W1588931589 cites W2088407876 @default.
• W1588931589 cites W2101995865 @default.
• W1588931589 cites W2122553809 @default.
• W1588931589 cites W2130652363 @default.
• W1588931589 cites W2131510486 @default.
• W1588931589 cites W2134667653 @default.
• W1588931589 cites W2153477391 @default.
• W1588931589 cites W4231481744 @default.
• W1588931589 doi "https://doi.org/10.1111/1759-7714.12267" @default.
• W1588931589 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4567010" @default.
• W1588931589 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26445613" @default.
• W1588931589 hasPublicationYear "2015" @default.
• W1588931589 type Work @default.
• W1588931589 sameAs 1588931589 @default.
• W1588931589 citedByCount "7" @default.
• W1588931589 countsByYear W15889315892015 @default.
• W1588931589 countsByYear W15889315892016 @default.
• W1588931589 countsByYear W15889315892017 @default.
• W1588931589 countsByYear W15889315892018 @default.
• W1588931589 countsByYear W15889315892021 @default.
• W1588931589 crossrefType "journal-article" @default.
• W1588931589 hasAuthorship W1588931589A5003642180 @default.
• W1588931589 hasAuthorship W1588931589A5008382997 @default.
• W1588931589 hasAuthorship W1588931589A5027834918 @default.
• W1588931589 hasAuthorship W1588931589A5045176687 @default.
• W1588931589 hasAuthorship W1588931589A5048001385 @default.
• W1588931589 hasAuthorship W1588931589A5053708169 @default.
• W1588931589 hasAuthorship W1588931589A5055470683 @default.
• W1588931589 hasAuthorship W1588931589A5065208984 @default.
• W1588931589 hasAuthorship W1588931589A5065246588 @default.
• W1588931589 hasAuthorship W1588931589A5068920157 @default.
• W1588931589 hasAuthorship W1588931589A5078718147 @default.
• W1588931589 hasBestOaLocation W15889315891 @default.
• W1588931589 hasConcept C121608353 @default.
• W1588931589 hasConcept C126322002 @default.
• W1588931589 hasConcept C143998085 @default.
• W1588931589 hasConcept C146357865 @default.
• W1588931589 hasConcept C151730666 @default.
• W1588931589 hasConcept C2776256026 @default.
• W1588931589 hasConcept C2776694085 @default.
• W1588931589 hasConcept C2776907518 @default.
• W1588931589 hasConcept C2777714996 @default.
• W1588931589 hasConcept C2778164965 @default.
• W1588931589 hasConcept C2779013556 @default.
• W1588931589 hasConcept C2779438470 @default.
• W1588931589 hasConcept C2780580887 @default.
• W1588931589 hasConcept C2781182431 @default.
• W1588931589 hasConcept C71924100 @default.
• W1588931589 hasConcept C86803240 @default.
• W1588931589 hasConceptScore W1588931589C121608353 @default.
• W1588931589 hasConceptScore W1588931589C126322002 @default.
• W1588931589 hasConceptScore W1588931589C143998085 @default.
• W1588931589 hasConceptScore W1588931589C146357865 @default.
• W1588931589 hasConceptScore W1588931589C151730666 @default.
• W1588931589 hasConceptScore W1588931589C2776256026 @default.
• W1588931589 hasConceptScore W1588931589C2776694085 @default.
• W1588931589 hasConceptScore W1588931589C2776907518 @default.
• W1588931589 hasConceptScore W1588931589C2777714996 @default.
• W1588931589 hasConceptScore W1588931589C2778164965 @default.
• W1588931589 hasConceptScore W1588931589C2779013556 @default.
• W1588931589 hasConceptScore W1588931589C2779438470 @default.
• W1588931589 hasConceptScore W1588931589C2780580887 @default.
• W1588931589 hasConceptScore W1588931589C2781182431 @default.
• W1588931589 hasConceptScore W1588931589C71924100 @default.
• W1588931589 hasConceptScore W1588931589C86803240 @default.
• W1588931589 hasIssue "5" @default.
• W1588931589 hasLocation W15889315891 @default.
• W1588931589 hasLocation W15889315892 @default.
• W1588931589 hasLocation W15889315893 @default.
• W1588931589 hasLocation W15889315894 @default.
• W1588931589 hasOpenAccess W1588931589 @default.
• W1588931589 hasPrimaryLocation W15889315891 @default.
• W1588931589 hasRelatedWork W1803443763 @default.
• W1588931589 hasRelatedWork W2312235271 @default.
• W1588931589 hasRelatedWork W2387455091 @default.

• next